Investors might want to bet on Compugen (CGEN) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. Analysts' growing optimism on the earnings prospects of this drug developer is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate ...

Compugen Ltd. (NASDAQ:CGEN) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Tony Butler - Rodman & Ren ...

Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 75%. A quarter ago, it was expected that this drug developer would post a loss of $0.10 per share when it actually produced a loss of $0.08, delivering a surprise of 20%. Over the last four quarters, the company has surpassed co ...

FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024 Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential r ...

Core Insights - The FDA has granted clearance for Compugen's investigational new drug application for COM503, leading to a $30 million milestone payment from Gilead [1][2] - Compugen plans to initiate a Phase 1 trial for COM503 in advanced solid tumors in Q4 2024 [1][2] Company Overview - Compugen Ltd. is a clinical-stage cancer immunotherapy company specializing in computational target discovery [5] - The company has two proprietary product candidates in Phase 1 development: COM701 and COM902, alongside COM503 [5] COM503 Details - COM503 is a high affinity anti-IL-18 binding protein antibody, which is being developed as a monotherapy and in combination with Gilead's anti-PD-1 antibody, zimberelimab [3][4] - The Phase 1 trial will assess the safety and tolerability of COM503 in participants with advanced or metastatic solid tumors globally [3] Partnership with Gilead - In 2023, Compugen and Gilead entered a license agreement granting Gilead exclusive rights to develop and commercialize anti-IL-18 binding protein antibodies, including COM503 [4] - Gilead provided an upfront payment of $60 million and will make additional milestone payments, with a total deal value of up to $848 million [4]

HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France. About Compugen Company contact: Yv ...

A downtrend has been apparent in Compugen (CGEN) lately. While the stock has lost 10.3% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings ...

HOLON, Israel, May 30, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical- stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT an ...

Financial Data and Key Metrics Changes - As of March 31, 2024, the company had approximately $101.3 million in cash, up from approximately $51.1 million as of December 31, 2023, reflecting a significant increase due to a $60 million upfront payment from Gilead and a $10 million milestone payment from AstraZeneca [16][17] - Revenue for Q1 2024 was approximately $2.6 million, compared to no revenue for the same period in 2023, indicating the recognition of a portion of the upfront payment from the licensing agreement with Gilead [17] - The net loss for Q1 2024 was $7.3 million, or $0.08 per share, compared to a net loss of $9.3 million, or $0.11 per share, in Q1 2023, showing an improvement in loss per share [18] Business Line Data and Key Metrics Changes - The company completed enrollment of more than 20 patients in its platinum-resistant ovarian cancer study, with initial findings expected in Q4 2024 [4][5] - The ongoing proof of concept study in MSS-CRC patients is set to present data at the ASCO conference in June 2024, focusing on the anti-tumor activities of COM701 in combination with COM902 and pembrolizumab [4][8] Market Data and Key Metrics Changes - The company is advancing the development of rilvegostomig in collaboration with AstraZeneca, which is initiating a second Phase 3 trial in non-squamous non-small cell lung cancer [4][12] - The company has identified significant unmet medical needs in MSS-CRC patients with liver metastasis, which represents a hard-to-treat population [8] Company Strategy and Development Direction - The company aims to leverage its validated AI/ML-powered discovery platform to enhance its pipeline and address cancer immunotherapy resistance [7] - The focus for 2024 includes multiple data readouts and updates from a diversified portfolio, with plans to submit an IND for COM503 in the second half of the year [12][19] - The company is considering various combinations for its therapies, including potential combinations with chemotherapy and other agents in ovarian cancer and non-small cell lung cancer [31][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's fundamentals and pipeline, highlighting the potential for long-term value creation for shareholders and cancer patients [19] - The management acknowledged the challenges in the current operating environment, particularly in targeting MSS-CRC with liver metastasis, and indicated a strategic pivot towards other combinations or indications in the future [22][38] Other Important Information - The company has no debts and expects a cash runway into 2027, taking into account expected milestone payments from Gilead [17][14] - The company is in advanced stages of planning for the Phase 1 study of COM503, with IND clearance expected in 2024 [12][19] Q&A Session Summary Question: Details on colorectal trials and future path - Management indicated that the presentation on June 1 will provide additional details beyond the abstract, including antitumor reactivity and safety data, but emphasized that IO-IO combinations may not be the right approach for MSS-CRC with liver metastasis [21][22] Question: Strategy for COM503 and clinical data disclosure - The decision to disclose clinical data for COM503 will be made in collaboration with Gilead, with IND filing expected in the second half of the year [22] Question: Combining with standard of care agents - Management acknowledged the potential for combining therapies with standard care agents like chemotherapy or VEGF in ovarian cancer, while focusing on the current IO combination strategy [31][41]

Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this drug developer would post earnings of $0.10 per share when it actually produced earnings of $0.11, delivering a surprise of 10%. Investors should be mindful of the fact that the outl ...